INT78707

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.05
First Reported 1998
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 1.43
Pain Relevance 0.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (Ksr1) kinase activity (Ksr1) cytoplasm (Ksr1)
Ksr1 (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 22 96.16 Very High Very High Very High
stellate ganglion block 7 92.32 High High
Pain 1 25.00 Low Low
headache 1 25.00 Low Low
Inflammation 6 5.00 Very Low Very Low Very Low
cINOD 2 5.00 Very Low Very Low Very Low
antagonist 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 25 99.78 Very High Very High Very High
Apoptosis 2 96.88 Very High Very High Very High
Breast Cancer 7 95.64 Very High Very High Very High
Colon Cancer 10 91.72 High High
Thyroid Neoplasm 2 81.36 Quite High
Hepatitis B Virus Infection 2 79.20 Quite High
Polyps 4 77.04 Quite High
Hepatitis 6 75.00 Quite High
Ganglion Cysts 1 70.68 Quite High
Malignant Neoplastic Disease 1 62.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
There were significant increases in rSO2 and Hb I in the blocked side and decreases in rSO2 and Hb I in the contralateral side.
Negative_regulation (decreases) of Hb I
1) Confidence 0.05 Published 1998 Journal Masui Section Abstract Doc Link 9834598 Disease Relevance 0.07 Pain Relevance 0.57
tumors through a reduction of cyclin D1 and HB-EGF [54] and an increase of p27Kip1 [55–57].
Negative_regulation (reduction) of HB-EGF associated with cancer
2) Confidence 0.02 Published 2008 Journal PPAR Research Section Body Doc Link PMC2430014 Disease Relevance 1.14 Pain Relevance 0.20
Of these, 11 failed to complete the study (4 on Hepacare and 7 on Recombivax-HB); however all but 2 (1 to receive the triple antigen vaccine and 1 to receive Recombivax-HB) were included in the intent-to-treat population for efficacy evaluation.
Negative_regulation (receive) of Recombivax-HB
3) Confidence 0.01 Published 2001 Journal J. Med. Virol. Section Abstract Doc Link 11424117 Disease Relevance 0.22 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox